Clinical Trial Update: Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line anlotinib plus durvalumab with platinum-etoposide for extensive-stage small-cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Durvalumab (durvalumab)
• Platinum–etoposide chemotherapy

Snippet

Sponsor: Henan Cancer Hospital | Conditions: SCLC, Extensive Stage | Phase 2 | Status: COMPLETED